Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

Benzer Materyaller

• Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
  Yazar:: Minhas, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  Yazar:: Neil, A, ve diğerleri
  Baskı/Yayın Bilgisi: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  Yazar:: Neil, H, ve diğerleri
  Baskı/Yayın Bilgisi: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
  Yazar:: Neil, H, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)
• CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
  Yazar:: M. Doortje Reijman, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-03-01)